This company listing is no longer active
Resumen acción GNHA.Y
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Competidores de Vifor Pharma AG
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$38.39 |
| 52 Week High | US$38.39 |
| 52 Week Low | US$31.18 |
| Beta | 1.04 |
| 1 Month Change | 4.19% |
| 3 Month Change | n/a |
| 1 Year Change | 9.67% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 26.97% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| GNHA.Y | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | 19.7% | -4.3% | -1.7% |
| 1Y | 9.7% | 14.6% | 22.9% |
Rentabilidad vs. Industria: GNHA.Y exceeded the US Pharmaceuticals industry which returned 5.8% over the past year.
Rentabilidad vs. Mercado: GNHA.Y exceeded the US Market which returned -22.8% over the past year.
Volatilidad de los precios
| GNHA.Y volatility | |
|---|---|
| GNHA.Y Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: GNHA.Y has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: Insufficient data to determine GNHA.Y's volatility change over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1872 | 2,200 | n/a | www.viforpharma.com |
Resumen de fundamentos de Vifor Pharma AG
| Estadísticas fundamentales de GNHA.Y | |
|---|---|
| Capitalización bursátil | US$10.78b |
| Beneficios(TTM) | US$157.07m |
| Ingresos (TTM) | US$1.94b |
15.9x
Ratio precio-beneficio (PE)1.3x
Ratio precio-ventas (PS)¿Está GNHA.Y sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de GNHA.Y | |
|---|---|
| Ingresos | CHF1.81b |
| Coste de los ingresos | CHF671.80m |
| Beneficio bruto | CHF1.14b |
| Otros gastos | CHF993.70m |
| Beneficios | CHF146.60m |
Últimos beneficios comunicados
Dec 31, 2021
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 2.26 |
| Margen bruto | 62.93% |
| Margen de beneficio neto | 8.09% |
| Ratio deuda/patrimonio | 13.6% |
¿Cómo se ha desempeñado GNHA.Y a largo plazo?
Ver rendimiento histórico y comparativa